This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 22:46, 13 November 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:46, 13 November 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages...)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2009) |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Molar mass | Antibodies in the 144.8 -148.8 kDa range |
| (what is this?) (verify) | |
Rozrolimupab (Sym001) is a polyclonal antibody used in the treatment of autoimmune thrombocytopenic purpura, prevention of isoimmunization in Rh-negative pregnant women.
This drug was developed by Symphogen A/S.
References
- STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ROZROLIMUPAB, American Medical Association.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |